Fusion Antibodies (LON:FAB) Shares Climb 14.8% – Should You Buy?

Shares of Fusion Antibodies plc (LON:FAB) were up 14.8% on Wednesday. The company traded as high as GBX 6.70 and last traded at GBX 6.31. 888,120 shares traded hands during trading, an increase of 97% from the average session volume of 451,622 shares. The stock had previously closed at GBX 5.50.

Fusion Antibodies Trading Up 0.6%

The company’s fifty day moving average is GBX 9.97 and its two-hundred day moving average is GBX 12.02. The stock has a market cap of £8.00 million, a price-to-earnings ratio of -6.39 and a beta of 1.24. The company has a quick ratio of 2.36, a current ratio of 2.82 and a debt-to-equity ratio of 20.41.

Fusion Antibodies (LON:FAB) last posted its quarterly earnings results on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative return on equity of 97.87% and a negative net margin of 54.45%. On average, research analysts predict that Fusion Antibodies plc will post -130.00 EPS for the current fiscal year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.